RICARDO ROMITI

(Fonte: Lattes)
Índice h a partir de 2011
22
Lattes
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/53 - Laboratório de Micologia, Hospital das Clínicas, Faculdade de Medicina
LIM/50 - Laboratório de Patologia das Moléstias Infecciosas, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Autor: HIRAYAMA, Andre Luis da Silva × Tipo de acesso: openAccess × Assunto: Psoriasis ×

Resultados de Busca

Agora exibindo 1 - 2 de 2
  • article 15 Citação(ões) na Scopus
    Generalized pustular psoriasis (von Zumbusch)
    (2022) ROMITI, Ricardo; HIRAYAMA, Andre Luis da Silva; ARNONE, Marcelo; MAGALHAES, Renata Ferreira
    Generalized pustular psoriasis (von Zumbusch) is a rare and acute eruption characterized by multiple sterile pustules over an erythematous and edematous background, eventually associated with psoriasis vulgaris. Classically, it manifests as a potentially severe systemic picture and demands prompt diagnosis and intervention. The duration of each flare-up and intervals between the pustular episodes is extremely variable. Recently, genetic abnormalities have been identified mainly in the familial and early variants of this disease. The therapeutic arsenal is limited; however, new drugs being evaluated aim to control both pustular flare-ups and disease recurrences. (C) 2021 Sociedade Brasileira de Dermatologia.
  • article 0 Citação(ões) na Scopus
    Infections in the era of immunobiologicals*
    (2024) ROMITI, Ricardo; HIRAYAMA, Andre Luis da Silva; PORRO, Adriana Maria; GONCALVES, Heitor de Sa; MIOT, Luciane Donida Bartoli; DURAES, Sandra Maria Barbosa; MARQUES, Silvio Alencar
    Immunobiologicals represent an innovative therapeutic option in dermatology. They are indicated in severe and refractory cases of different diseases when there is contraindication, intolerance, or failure of conventional systemic therapy and in cases with significant impairment of patient quality of life. The main immunobiologicals used in dermatology basically include inhibitors of tumor necrosis factor-alpha (anti-TNF), inhibitors of interleukin-12 and -23 (anti-IL12/23), inhibitors of interleukin-17 and its receptor (anti-IL17), inhibitors of interleukin-23 (anti-IL23), rituximab (anti-CD20 antibody), dupilumab (anti-IL4/IL13) and intravenous immunoglobulin. Their immunomodulatory action may be associated with an increase in the risk of infections in the short and long term, and each case must be assessed individually, according to the risk inherent to the drug, the patient general condition, and the need for precautions. This article will discuss the main risks of infection associated with the use of immunobiologicals, addressing the risk in immunocompetent and immunosuppressed patients, vaccination, fungal infections, tuberculosis, leprosy, and viral hepatitis, and how to manage the patient in the most diverse scenarios. (c) 2023 Published by Elsevier Espan similar to a, S.L.U. on behalf of Sociedade Brasileira de Dermatologia. This is an open access article under the CC BY license (http://creativecommons.org/licenses/ by/4.0/).